Methionine adenosyltransferase (MAT) is an essential cellular enzyme which catalyses the formation of S-adenosylmethionine, the principal methyl donor and precursor for polyamines. In mammals, two different genes, MAT1A and MAT2A, encode for liver-specific and non-liver-specific MAT respectively. We previously described a switch in the MAT expression from MAT1A to MAT2A in human liver cancer, which offered the cancerous cell a growth advantage. Loss of MAT1A expression was due to lack of gene transcription. To study regulation of the MAT1A gene, we have cloned and characterized a 1.9 kb 5h-flanking region of the human MAT1A gene. One transcriptional start site, located 25 nt downstream from a consensus TATA box, was identified by primer extension and RNase protection assays. The promoter contains several consensus binding sites for CAAT enhancer binding protein (C\EBP) and hepatocyte-enriched nuclear factor (HNF), transcriptional factors important in liver-
INTRODUCTION
Methionine adenosyltransferase (MAT) is a critical cellular enzyme which catalyses the formation of S-adenosylmethionine (SAM), the principal biological methyl donor and the ultimate source of the propylamine moiety used in polyamine biosynthesis [1, 2] . In mammals, two different genes, MAT1A and MAT2A, encode for two homologous MAT catalytic subunits, α1 and α2 [3] [4] [5] . MAT1A is expressed only in liver and encodes the α1 subunit found in two native MAT isoenzymes, which are either a dimer (MAT III) or tetramer (MAT I) of this single subunit [5] . MAT2A encodes for a catalytic subunit (α2) found in a native MAT isoenzyme (MAT II) which is widely distributed [3] [4] [5] . MAT2A also predominates in the foetal liver and is progressively replaced by MAT1A during development [6, 7] . In adults, increased expression of MAT2A is associated with rapid growth of the liver. We showed a switch in the gene expression from MAT1A to MAT2A in human liver cancer [8] and from 12 to 24 h after partial hepatectomy in the rat [9] . In liver cancer, absence of MAT1A expression is due to lack of gene transcription [8] . Using a cell-line model that differs only in the type of MAT expressed, we demonstrated that the type of MAT expressed by the cell significantly influences the rate of cell growth [10] . Specifically, MAT1A expression is associated with the lowest rate of cell growth, while the opposite is true of MAT2A expression [10] . Thus the switch in MAT expression in liver cancer plays an important pathogenetic role by facilitating liver cancer growth. To better understand gene regulation of human MAT1A, we Abbreviations used : MAT, methionine adenosyltransferase ; SAM, S-adenosylmethionine ; EMSA, electrophoretic-mobility-shift assay ; C/EBP, CAAT enhancer binding protein ; HNF, hepatocyte-enriched nuclear factor ; AP-1, activator protein-1 ; IL-6, interleukin-6 ; GRE, glucocorticoid response element ; CRE-BP, cAMP-response-element-binding protein ; CMV, cytomegalovirus. 1 To whom correspondence should be addressed (e-mail shellylu!hsc.usc.edu). The sequence of the 1.9 kb 5h-flanking region of the human MAT1A gene has been deposited with the EMBL, GenBank2 and DDJB Nucleotide Sequence Databases under the accession number AF110500. specific gene expression. The human MAT1A promoter was able to efficiently drive luciferase expression in Chang cells, a human liver cell line, but not in HeLa cells. Sequential deletion analysis of the promoter revealed two DNA regions upstream of the translational start site, k705 to k839 bp and k1111 to k1483 bp, which are involved in positive and negative gene regulation, respectively. Specific protein binding to these regions was confirmed by electrophoretic-mobility-shift and DNase I footprinting assays. Similar to the situation with the rat MAT1A, glucocorticoid treatment also increased human MAT1A expression and promoter activity in a dose-and time-dependent manner.
Key words : Chang cells, glucocorticoid, luciferase expression, electrophoretic mobility shift, DNase I footprinting analysis cloned and characterized the 5h-flanking region of the human MAT1A, the gene that encodes the catalytic subunit of liverspecific MAT.
MATERIALS AND METHODS

Materials
Cell-culture media and foetal bovine serum were obtained from Gibco BRL Life Technologies (Grand Island, NY, U.S.A.). The Luciferase Assay System and the β-Galactosidase Enzyme Assay System were obtained from Promega (Madison, WI, U.S.A.). All restriction enzymes were obtained from either Promega or Gibco. Triamcinolone was obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.).
Source of normal human liver tissue
Normal liver tissue was resected from liver specimens of patients with metastatic colon or breast carcinoma. Written informed consent was obtained from each patient. Tissues were immediately frozen in liquid nitrogen for subsequent isolation of nuclear protein as described in [11] .
The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by University of Southern California School of Medicine's Human Research Review Committee.
Cloning of the 5h-flanking region of the human MAT1A gene
To clone the promoter region of the human MAT1A gene, the Genome Walker kit (ClonTech, Palo Alto, CA, U.S.A.) was used according to manufacturer's instructions. All oligonucleotide primers used in this study were synthesized by the Molecular Biology Core of the Liver Disease Research Center, USC School of Medicine. Human MAT1A-specific primary PCR primer sequence is 5h-GTCACACAAGCCATCCACCG-3h, which is the reverse of, and complementary to, j30 to 11 nt downstream of the translational start site of the human MAT1A gene [4] . The secondary PCR primer is 5h-TTCATCTTCTCACACTTCTC-CACTC-3h, which is the reverse of, and complementary to, k20 (upstream) to j5 nt (downstream) of the translational start site. PCR reactions were performed using a Perkin-Elmer DNA Thermal Cycler 480 with the following conditions : 94 mC for 25 s and 72 mC for 4 mini7 cycles ; 94 mC for 25 s and 67 mC for 4 mini32 cycles, followed by a 4 min final extension at 67 mC. Secondary PCR was conducted using 1 µl of a 50-fold dilution of the primary PCR product as template, the same reaction composition and cycle parameters, with the exception that 20 thermocycles were performed instead of 32. PCR products were analysed on a 1.2 % (w\v) agarose\ethidium bromide gel. Using this technique, we were able to identify a single major PCR product from three of the five libraries (EcoRV, DraI, SspI) provided in the Genome Walker kit. The largest PCR product was 1.9 kb which was obtained using the SspI library. This product was purified from the gel by QIAquick Gel Extraction kit (Qiagen, Valencia, CA, U.S.A.), cloned into pT-Adv (ClonTech) and sequenced in both directions using the automated ABI Prism dRhodamine Terminator Cycle Sequencer performed by the Sequencing and Genetic Analysis Core Facility, Department of Cell and Neurobiology, USC School of Medicine. The initial primers were universal primers for the pT-Adv vector, all subsequent primers were nested primers designed using the available sequence information and the MacVector software program. The nucleotide sequence was verified by multiple bidirectional sequencing reactions. Sequences were aligned and a consensus sequence generated using the ASSEMBLIGN software program.
Primer extension analysis
Primer extension analysis was performed as described in [12] . Two antisense oligonucleotide primers complementary to nt j46 to j75 and k38 to k9 relative to the translational start site of the human MAT1A [4] were end-labelled with [γ-$#P]ATP using T % polynucleotide kinase. A 2.5 µg portion of polyadenylated RNA from human liver isolated as described [13] (or yeast tRNA as a negative control) was annealed to 10' c.p.m. of the primer and extended with 200 units of Moloney-murine-leukaemia-virus reverse transcriptase (Superscript II ; Life Technologies). The primer-extended products were analysed on 7 M urea\6 % polyacrylamide gels.
RNase protection assay
RNase protection assay was done according to instructions provided in the Multi-NPA4 manual (Ambion, Austin, TX, U.S.A.). The probe was synthesized by linear amplification, the primer was 5h-GTCACACAAGCCATCCACCG-3h, which is the reverse of, and complementary to, j30 to j11 nt downstream of the translational start site [4] and the template was a BpuA1-digested fragment (362 bp) from the 1.9 kb 5h-flanking region.
Construction of 5h-deletion constructs
The 1.9 kb PCR product, representing the MAT1A 5h-flanking region, was cloned in the sense orientation upstream of the luciferase coding sequence of the pGL3-enhancer vector (Promega). The resulting plasmid, designated pMAT1A-Luc, is the construct that contains the longest 5h-flanking sequence (k1902 to j30) employed in the transfection assay. To prepare 5h-deletion constructs, pMAT1A-Luc was digested with Acc65I and one internal restriction enzyme. The internal restriction enzymes used for generating deletion constructs were NdeI (k1483 to j30), Tth111I (k1111 to j30), and P uII (k705 to j30). Between the P uII and Tth111I sites, we constructed another 5h-deletion (k839 to j30) using the Erase-a-Base System Kit (Promega) including an exonuclease III which only digests 5h-overhangs or blunt-end sites. The resulting DNA fragments containing the luciferase expression vector were blunt-ended by Klenow (Gibco) and self-ligated by T4 DNA ligase (ClonTech).
Analysis of promoter constructs in cell culture
Normal human liver cell line Chang (A.T.C.C. no.CCL-13) and human cervix epitheloid carcinoma cell line HeLa (A.T.C.C. no.CCL-2) were cultured according to instructions provided. We chose to study expression in Chang cells because MAT1A is expressed only in the liver. HeLa cells were included for comparison because the Chang cells obtained from A.T.C.C. may be contaminated with HeLa cells (see description of Chang cells in the A.T.C.C. catalogue). To study the relative transcriptional activities of the MAT1A promoter fragments, Chang and HeLa cells (1i10' cells in 4 ml of medium) were transiently transfected with 8 µg of MAT1A promoter luciferase gene construct, promoterless pGL3-enhancer vector (as negative control) or CMV-pGL3-enhancer-Luc construct (as positive control) and 2 µg of a β-galactosidase expression plasmid (as an internal standard of transfection efficiency) using the calcium phosphate precipitation method [14] . After 48 h, cells were harvested and lysed in 1 ml of reporter lysis buffer (Luciferase Assay System ; Promega). The luciferase assay was performed on 20 µl of the cleared lysate and 100 µl of luciferase assay reagent using a TD-20\20 Luminometer (Promega). The β-galactosidase assay was done according to the supplier's instructions using 150 µl of the cell lysate. Protein concentration was determined using the BioRad Protein Assay. The luciferase activity of each transfection was expressed as luciferase activity per β-galactosidase activity per protein concentration.
Effect of triamcinolone on MAT1A expression in Chang cells
Triamcinolone has been shown to increase the MAT1A expression in rats via an increase in transcriptional activity [15] . To see if triamcinolone exerts a similar effect on human MAT1A expression, Chang cells were treated with triamcinolone (0.01-1µM) in the culture medium for 24 h or 0.1 µM for 6-48 h. At the end of the treatment, total RNA was extracted from Chang cells as described in [8] and the steady-state MAT1A mRNA level was determined using a specific MAT1A cDNA probe [8] . To ensure equal loading of RNA samples and transfer in each of the lanes prior to hybridization, membranes were rinsed with ethidium bromide and photographed. The same membranes were also rehybridized with $#P-labelled β-actin or 18 S cDNA probes as described in [9, 11] . Autoradiography and densitometry (Gel Documentation System ; Scientific Technologies, Carlsbad, CA, U.S.A. and NIH Image 1.60 software program) were used to quantify relative RNA. Results of Northern-blot analysis were normalized to β-actin or 18 S probe. Functional analysis of the human methionine adenosyltransferase 1A promoter To examine the effect of triamcinolone on the human MAT1A promoter activity, Chang cells transfected with the human MAT1A promoter luciferase constructs were treated with triamcinolone (100 nM) or vehicle for 12, 24 or 44 h. For the 12 and 24 h treatments, cells were transfected for 28 h in total. Triamcinolone was added during the last 12 or 24 h. For the 44 h treatment, cells were transfected for 48 h in total. Luciferase activities driven by the human MAT1A promoter constructs in Chang cells were essentially the same in vehicle-treated controls regardless of the duration of transfection, and were pooled for analysis.
Electrophoretic-mobility-shift assay (EMSA)
EMSAs for positive and negative regulatory regions were done as described in [11, 12] . A 15 µg portion of nuclear protein from normal human liver or Chang cells was pre-incubated with 2 µg of poly(dI-dC) in a buffer containing 10 mM Hepes (pH 7.6), 50 mM KCl, 0.1 mM EDTA, 1 mM dithiothreitol, 5 mM MgCl # and 10 % (v\v) glycerol for 10 min on ice. $#P-end-labelled double-stranded DNA fragments (positive fragment, k830 to k705 ; negative fragments, k1451 to k1309 and k1327 to k1225) were then added with or without a 50-fold excess of In primer extension, two 32 P-end-labelled primers complementary to nt j46 to j75 (primer 1 or P1) and k38 to k9 (primer 2 or P2) of the human MAT1A cDNA were annealed to human liver polyadenylated RNA or yeast tRNA (primer 2 used) and extended with reverse transcriptase as described in the Methods section. In the RNase-protection assay, the primer was the reverse of, and complementary to, nt j30 to j11 of the human MAT1A. In the presence of RNA, a product of 268 nt was obtained. Size markers correspond to φX174 digested with Hin f1.
unlabelled specific or non-specific probe as competitor. Mixtures were incubated for 20 min on ice, loaded on a 4 % non-denaturing polyacrylamide gel and subjected to electrophoresis in 50 mM Tris\45 mM borate\0.5 mM EDTA, pH 8.0. Gels were dried and subjected to autoradiography.
DNase I footprinting analysis
Two $#P-end-labelled fragments of the 5h-flanking region of human liver MAT1A gene were generated by digestion with restriction endonucleases. The fragment k976 to k504 was generated by digestion with Msp1 (k976) and Sty1 (k507), and the fragment k1483 to k1149 was generated by digestion with Nde1 (k1483) and Sty1 (k1152). Singly end-labelled fragments were generated by filling 5h-protruding ends with [α-$#P]dCTP (3000 Ci\mmol) or [α-$#P]dATP (3000 Ci\mmol) using the exoKlenow enzyme. In addition, the fragment k1483 to k976 was labelled by [γ-$#P]ATP using T4 polynucleotide kinase and digested with Sty1 (k1152) for subsequent sequencing (k1483 to k1152). Labelled probes were purified by electrophoresis with 2 % agarose gel. Approx. 5i10% c.p.m. of end-labelled DNA fragments were incubated with 15-45 µg of nuclear protein from normal human liver. After 30 min incubation on ice, CaCl # and MgCl # were added to give a final concentration of 0.5 mM and 1 mM respectively. DNase I digestions were performed at room temperature for 1 min. Upon phenol extraction and ethanol precipitation, DNA fragments were resolved by electrophoresis in a denaturing 8 % acrylamide sequencing gel.
Statistical analysis
Data are given as meanpS.E.M. Statistical analysis was performed using analysis of variance (ANOVA) followed by Fisher's test for multiple comparisons. Significance was defined as P 0.05.
RESULTS
Cloning and sequencing of the 5h-flanking region of the human MAT1A
The sequence of the 1.9 kb product is shown in Figure 1 . A canonical TATA box is located 263-268 nt upstream of the translational start site. Analysis of the transcription-factorbinding sites was done using Transcription Factor Search (Internet address : http :\\www.pdap1.trc.rwcp.or.jp\research\ db\TFSEARCH.html). The 5h-flanking region of the human Functional analysis of the human methionine adenosyltransferase 1A promoter Progressive 5h-deletions of the MAT1A promoter extending from k1902 to j30 bp were generated and fused to the promoterless luciferase pGL-3 enhancer vector as described in the Methods section. Numbering is defined relative to the translational start site. Results represent meanpS.E.M. from three to six independent experiments performed in triplicate. Triamcinolone treatment (100 nM) was for 12, 24 or 44 h. The luciferase activity of each transfection was expressed as luciferase activity/β-galactosidase activity/protein concentration. Data is expressed as relative luciferase activity to that of pGL-3 enhancer vector control, which is assigned a value of 1.0. *P 0.05 versus the pGL-3 enhancer control, k705/j30-LUC and k1483/j30-LUC constructs ; †P 0.05 versus triamcinolone treatments of different durations ; **P 0.05 versus 12 and 44 h triamcinolone treatments (analysis of variance followed by Fisher's test).
MAT1A contains several consensus binding sites for CAAT enhancer binding protein (C\EBP) and hepatocyte-enriched nuclear factor (HNF), transcriptional factors important in liverspecific gene expression [16, 17] . In addition, consensus binding sites for activator protein-1 (AP-1), CAAT, interleukin-6 (IL-6), glucocorticoid response element (GRE), cAMP response element binding protein (CRE-BP), E2F, PEA3, STATx, c-Myc and v-Myb are also present.
Transcriptional start site
Primer-extension analysis was first used to determine the transcriptional start site. Two antisense oligonucleotide primers complementary to j46 to j75 (primer 1) and k38 to k9 (primer 2) nt relative to the translational start site of the human MAT1A [4] were annealed to poly(A) + RNA from human liver and extended towards the 5h end of the mRNA by reverse transcription. Figure 2 shows the primer extension reaction, which yielded a product of approx. 311 nt long using primer 1 and a product of approx. 230 nt long using primer 2. These products were not detected when the assay was carried out using tRNA. These results are consistent with the transcriptional start site being located approx. 25-27 nt downstream of the consensus TATA box or about 236-238 nt upstream of the translational start site. To further delineate and confirm the transcriptional start site, an RNase protection assay was carried out. Using a primer that is the reverse of, and complementary to, j30 to 11 nt downstream of the translational start site, a product of 268 nt was obtained (Figure 2 ). This confirms that the transcriptional start site is at 238 nt upstream of the translational start site.
Figure 4 Effect of triamcinolone on steady-state MAT1A mRNA levels in Chang cells
Chang cells were treated with various doses of triamcinolone for 24 h (top panel) or with 0.1 µM at the time points shown (bottom panel). Total RNA (30 µg each lane) samples were extracted from these cells and analysed by Northern-blot hybridization with a 32 P-labelled MAT1A cDNA probe as described in the Methods section. The same membranes were then rehybridized with 32 P-labelled β-actin or 18 S cDNA probes. Representative Northern blots are shown.
Functional analysis of the 5h-flanking region of human MAT1A
To delineate sequences that drive the expression of the human MAT1A, five 5h-terminal nested deletion mutants ranging from k1902\j30 to k705\j30 were cloned into the promoterless luciferase reporter gene vector pGL3-enhancer. The promoterless construct pGL3-enhancer served as the background control. Luciferase activity was measured after transient transfection of Chang and HeLa cells with these constructs. Figure 3 shows that the human MAT1A promoter was able to efficiently drive luciferase expression in Chang cells but not in HeLa cells. In contrast, the CMV promoter was able to drive luciferase expression in both cell types (luciferase activity is 106p21-fold and 544p27-fold over pGL-3 enhancer control in Chang and HeLa cells respectively ; results represent meanspS.E.M. from three to four independent experiments). In Chang cells, the construct k1111\j30 showed maximal promoter activity, the construct k839\j30 produced 80 % of maximal activity, whereas the construct k705\j30 produced only 25 % of maximal activity, indicating the presence of important elements between k705 and k839 that positively regulate promoter activity. The presence of negative regulatory elements is also suggested in the region of k1111 to k1483 as the construct k1483\j30 produced 22 % of the maximal activity, while constructs k1111\j30 and k1902\j30 both produced maximal activity.
Effect of triamcinolone on MAT1A mRNA level and MAT1A promoter activity
The effect of triamcinolone on MAT1A mRNA expression in Chang cells is shown in Figure 4 . A clear dose-and time-
Figure 5 EMSAs for regions implicated in regulation of the human MAT1A
Nuclear protein extracts were obtained from normal human liver (triplicates) and EMSA was done as described in the Methods section using probes that span these regions. The arrows point to specific complexes which were competitively blocked by 50-fold excess of unlabelled specific probe. Similar results were obtained using nuclear protein extracts from Chang cells (results not shown).
dependent effect on the MAT1A expression is evident. After 24 h of treatment, 0.1 µM triamcinolone produced the maximal increase in the steady-state MAT1A mRNA level. A time course was then established using 0.1 µM triamcinolone. Maximal effect occurred as early as 6 h after treatment and returned towards baseline by 36 h. Consistent with this, triamcinolone exerted a significant increase in the luciferase expression driven by MAT1A constructs k1111\j30 and k839\j30 when the treatment was for 12 or 24 h. However, it exerted little effect on the luciferase expression if the treatment was for 44 h (Figure 3) .
Analysis of regulatory regions using EMSA
On the basis of results of the deletion analysis, EMSAs were carried out using probes that span regions implicated in positive or negative regulation of the human MAT1A. The region k839 to k705 increased the promoter activity by 300 %, whereas the region k1483 to k1111 reduced the promoter activity by 80 %. Figure 5 shows that there is specific protein binding to these regions. The same results were obtained using nuclear proteins from normal human liver or Chang cells.
DNase I footprinting analysis of human MAT1A 5h-flanking region.
To further characterize the regulatory regions, DNase I footprinting analysis was carried out. Figure 6 shows that four nuclear-protein-dependent DNase I-protected areas are present in both strands in the region k976 to k504 of the human MAT1A promoter. Four nuclear-protein-dependent DNase Iprotected areas are also present in both strands in the region k1483 to k1149 (Figure 7) .
DISCUSSION
In mammals, two distinct genes encode for the enzyme MAT [3] [4] [5] . MAT1A is a liver-specific gene which is expressed in the liver shortly before birth and becomes the major form of MAT as the liver matures [7] . It is a marker for differentiated or mature liver phenotype. In contrast, MAT2A is expressed in all nonhepatic tissues as well as during periods of rapid liver growth [3, [6] [7] [8] [9] [10] . Although the two MAT genes are highly homologous, the enzymes they encode have different kinetic profiles and regulatory properties [18] . Due to these differences, the type of MAT expressed by a cell can influence the cell's steady state SAM level, methylation status and growth rate [10] .
Decreased activity of liver-specific MAT is well known in various liver diseases and may contribute to the pathogenesis of liver injury [1, 18] . Both transcriptional and post-transcriptional regulation of liver-specific MAT have been described [1, 15, [18] [19] [20] [21] [22] [23] [24] [25] . Most of the studies have focused on post-translational regulation of liver-specific MAT [1, 18, [22] [23] [24] [25] . The liverspecific MAT contains several critical cysteine residues. Modifications of these residues can inactivate the enzyme by direct interference with the substrate-binding site(s) or by causing alteration in the oligomeric equilibrium (a decrease in the ratio of tetramer to dimer, which is less active at physiological substrate concentrations) [1, 18, [22] [23] [24] . We have also speculated recently that liver-specific MAT protein may be degraded more rapidly after treatment of rats with thioacetamide [25] . Less is known about transcriptional regulation. In rodents, glucocorticoid has been shown to increase MAT1A transcription and possibly mRNA stability [15, 19] . On the other hand, prolonged hypoxia led to decreased MAT1A transcription and mRNA stability [21] . The only human condition where MAT1A gene transcription is altered is liver cancer, where MAT1A transcription is markedly reduced or absent [8] . Genomic cloning of human MAT1A was reported by Ubagai and colleagues [26] ; however, the sequence of the promoter was not examined. To better understand transcriptional regulation of human MAT1A, we have cloned and characterized the 1.9 kb 5h-flanking region.
The sequence of 5h-flanking region of the human MAT1A shares little similarity to the 5h-flanking region of the rat or murine MAT1A [12, 19] and no similarity to the 5h-flanking region of the human MAT2A [27] . Primer extension and RNase protection assays revealed a single transcriptional start site located 25 nt downstream of a putative TATA box or 238 nt upstream of the translational start site (Figure 2 ). This differs from the results of Alvarez and colleagues, which estimated the transcriptional start site to be approx. 90 nt upstream of the translational start site [4] . The explanation for this discrepancy is unclear. We confirmed the start site, however, using different primers and assays, and its proximity to the consensus TATA box further support the validity of our results. Although the sequence of the human MAT1A promoter shares little similarity with the rat MAT1A promoter, both contain several consensus binding sites for HNF, CAAT and GRE, and one or more binding sites for IL-6, PEA3 and AP-1 [12] . In addition, the human MAT1A promoter also contain several consensus binding sites for C\EBP and one or more sites for CRE-BP, E2F, STATx, c-Myc and vMyb. HNF and C\EBP are transcriptional factors important in liver-specific gene expression [15, 16] . Whether they are functionally active in mediating the liver-specific expression of MAT1A will require further study.
Transfection studies showed that the 5h-flanking sequence of the human MAT1A gene contained a functional promoter which was able to drive luciferase expression in Chang cells efficiently but not in HeLa cells. In Chang cells, the maximal activity was about 18-fold over that of vector control, whereas in HeLa cells the maximal activity was only 3-fold over that of vector control. This difference was not due to efficiency of transfection as luciferase activity, driven by the CMV promoter was actually 5-fold higher in HeLa cells. This suggests that the transfection efficiency was actually lower in Chang cells than in HeLa cells. Thus the difference in MAT1A promoter-driven luciferase expression in the two cell types is likely to be an underestimate of the true difference. The results also suggest cell-type specific transcriptional factors may be involved in mediating differential expression of human MAT1A. This contrasts with studies using the rat MAT1A promoter-luciferase chimaeric constructs, which exhibited activity in both liver-type cells and Chinese-Hamster cells [12] . Further studies are required to better understand these species differences.
Two regions in the human MAT1A promoter are important for the overall activity. One is between k705 and k1111 bp and another is between k1111 and k1483 bp, relative to the translational start site. The first region is involved in positive regulation, as luciferase expression increased more than 4-fold. The region between k705 and k839 bp is responsible for the bulk of the maximal activity. Specific protein binding to this region is demonstrated by EMSA. DNase I footprinting assay of the region from k976 to k504 revealed four protected areas in both strands, k620 to k660, k680 to k728, k750 to k840 and k852 to k870. Consensus binding sites in these regions include CAAT, C\EBP-β, USF, c-Myc and GRE. The region between k1111 to k1483 bp is involved in negative regulation as inclusion of this region decreased the luciferase activity by nearly 80 %. Specific protein binding to the region from k1451 to k1225 bp is also demonstrated by EMSA. DNase I footprinting assay of the region from k1483 to k1149 revealed several protected areas in both strands, k1200 to k1262, k1286 to k1318, k1328 to k1345 and k1360 to k1412. Potential binding sites in these regions include PEA3, AP-1, Sox-5, C\EBP-β and E2F. The binding site for E2F, k1384 to k1377 (TTTGGAGC), differs by one nt from the consensus E2F-binding site (TTTSSCGC, where SS l C or G) [28] . E2F has been shown to act as a repressor for many genes that are important for cell cycle control [28] . Further work will be required to define the involvement of these cis-acting elements and transactivating\repressor proteins in the regulation of human MAT1A promoter. The negative effect of this region on luciferase activity was overcome by insertion of 420 bp upstream, suggesting the possible presence of enhancer elements in the region from k1902 to k1483. Further studies are required to confirm their presence.
Glucocorticoid induced a 3-fold increase in the rat MAT1A promoter activity [15] . The human MAT1A promoter also contains several consensus GRE-binding sites, and one of these (k847 to k842) was shown to be included in the DNase Iprotected regions. Glucocorticoid exerted a strong dose-and time-dependent effect on the human MAT1A expression in Chang cells. Maximum effect was observed with 0.1 µM triamcinolone after 6 h treatment. MAT1A expression remained elevated until some time between 36 and 48 h after treatment. This was reflected in the luciferase expression driven by the human MAT1A promoter constructs. Triamcinolone treatment increased promoter activity in the 12 and 24 h-treated cells but not the 44 h-treated cells. Triamcinolone exerted the largest increase in luciferase activity (4.5-fold) in the k839\j30 promoter construct. Three consensus GRE sites are present in this region, k514 to k509, k211 to k206 and k173 to k168. Additional work will be necessary to delineate the involvement of these sites. Triamcinolone exerted little effect with constructs k1483\j30 and k1902\j30. It appears that the presence of the strongly negative influence in the upstream region dominated any positive effect glucocorticoid may have. Alternatively, additional elements upstream of k1902 may be present that are important for the overall glucocorticoid effect.
In summary, we have cloned and analysed the 5h-flanking region of the human MAT1A gene. This will facilitate future studies examining transcriptional regulation of the human MAT1A gene. 
